Shareholders That Lost Money on GSK plc (GSK) Should Contact Levi & Korsinsky about Pending Class Action - GSK
Portfolio Pulse from
Law firm Levi & Korsinsky has filed a class action securities lawsuit against GSK plc, alleging the company misled investors about Zantac's safety and NDMA risks between February 2020 and August 2022. The lawsuit claims GSK knew about NDMA sources for decades before withdrawing the drug from the market, potentially causing financial losses for shareholders.
March 21, 2025 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The class action lawsuit could result in significant financial liability and potential stock price impact for GSK, stemming from alleged misrepresentations about Zantac's safety and NDMA risks.
The lawsuit alleges systematic misrepresentation about Zantac's safety, which could lead to substantial legal costs, potential settlements, and investor trust erosion.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100